Bioanalysis Zone

Does validation stagnate innovation?


“…dried blood spots. Here was something that completely got round all the problems I had witnessed and many less funny ones … I felt we were on the brink of a little revolution.”

At the end of 1999, I remember the planning we had to do to ensure that the millennium bug did not wreak havoc in the Department of Drug Metabolism, Pfizer Inc., UK. When we analyzed the vulnerable items, most would be powered down (switched off) over the holiday break. What was left was the freezer and cold room network, protecting countless samples. Of course this had a microprocessor doing something and obviously it couldn’t be switched off. Our contingency plan was for Dick Venn, the senior analyst, to travel into the laboratories and check all was well early on New Years day.

To view restricted content, please:

Leave A Comment